Piramal Pharma Limited (PPLPHARMA) Net Income 2022–2026

Name: Piramal Pharma Limited (PPLPHARMA) net income history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Piramal Pharma Limited annual net income for fiscal 2026 was -₹3.3 billion, compared with ₹911 million in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

PPLPHARMA Annual Net Income

Net Income (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Net Income	(₹3.3B)	₹911M	₹178M	(₹1.9B)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PPLPHARMA Quarterly Net Income

Net Income (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31
Net Income	(₹694M)	(₹88M)	(₹1.4B)	(₹817M)	₹1.5B

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

WOCKPHARMA Net Income — Wockhardt Limited
1276 Net Income — Jiangsu Hengrui Pharmaceuticals Co.,Ltd
NEULANDLAB Net Income — Neuland Laboratories Limited
4540 Net Income — Tsumura & Co.
4516 Net Income — Nippon Shinyaku Co., Ltd.
3692 Net Income — Hansoh Pharmaceutical Group Company Limited

More PPLPHARMA metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All PPLPHARMA financial statements → Interactive PPLPHARMA charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.